Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07)

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 87-91

  Passweg, Jakob R ^a   Pabst, Thomas ^b   Blum, Sabine ^c   Bargetzi, Mario ^d   Li, Qiyu ^e   Heim, Dominik ^a   Stussi, Georg ^f   Gregor, Michael ^g   Leoncini, Leda ^h   Meyer Monard, Sandrine ⁱ   Brauchli, Peter ^e   Chalandon, Yves ^j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d CANTONAL HOSPITAL AARAU   (Switzerland)

^e SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g LUZERNER KANTONSSPITAL   (Switzerland)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ Institut Central des Hopitaux Valaisans   (Switzerland)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Chemotherapeutic approaches; Cytogenetics; Myeloid leukemias and dysplasias

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DECUBITUS; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FRAIL ELDERLY; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; MALE; METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RETINA DETACHMENT; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; FRAIL ELDERLY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84880750486     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.790540     Document Type: Article

References (22)

1. Burnett A, Wetzler M, Löwenberg B. Th erapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
2. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005; 106: 1154-1163.
3. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Available from: Http:// seer.cancer.gov/csr/ 1974-2004
4. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908-1915.
5. Wheatley K, Brookes CL, Howman AJ, et al. United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 2009; 145: 598-605.
6. Burnett AK, Milligan D, Prentice AG, et al. A comparison of lowdose cytarabine and hydroxyurea with or without all-Trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109: 1114-1124.
7. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. FIGHT-AML-301 Investigators. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114: 1166-1173.
8. Burnett A, Wetzler M, Löwenberg B. Th erapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-494.
9. Burnett AK, Hills RK, Hunter A, et al. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 2011; 25: 1122-1127.
10. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009 ;10: 223-232.
11. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-2440.
12. Itzykson R, Fenaux P. O ptimizing hypomethylating agents in myelodysplastic syndromes. Curr Opin Hematol 2012; 19: 65-70.
13. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28: 562-569.
14. Keating G M. Azacitidine: A review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia. Drugs 2009; 69: 2501-2518.
15. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Th erapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642-4649.
16. Lübbert M, Rüter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfi t for induction chemotherapy. Haematologica 2012; 97: 393-401
17. Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012; 26: 893-901.
18. Al-Ali HK, Jaekel N, Junghanss C, et al. A zacitidine in patients with acute myeloid leukemia medically unfi t for or resistant to chemotherapy: A multicenter phase I/II study. Leuk Lymphoma 2012; 53: 110-117.
19. Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012; 118: 1014-1022
20. Cashen AF, Schiller GJ, O ' Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
21. Borthakur G, Huang X, Kantarjian H, et al. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 2010; 51: 73-78.
22. Kantarjian HM, Th omas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670-2677.